|
|
|
|
|
Zymeworks Added To Nasdaq Biotechnology Index
|
Vancouver, BC, December 29, 2023--Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced it has been added to the Nasdaq Biotechnology Index.
|
|
|
|
|
|
|
Zymeworks Joins the Russell 3000, Russell 2000, And Russell Microcap Indexes
|
Vancouver, BC, July 14, 2023--Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced that it has recently joined both the Russell 3000, Russell 2000®, and the Russell Microcap® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective June 26, 2023.
|
|
|
|
|
|
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
|
Vancouver, BC, May 28, 2023--Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced the departure of Neil Klompas, President and Chief Operating Officer. Mr. Klompas joined Zymeworks in 2007 as Chief Financial Officer and served in multiple capacities until being named Chief Operating Officer and President in 2022.
|
|
|
|
|